The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia

Aim: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury — glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Methods: A t...

Повний опис

Збережено в:
Бібліографічні деталі
Опубліковано в: :Experimental Oncology
Дата:2010
Автори: Horacek, J.M., Vasatova, M., Tichy, M., Pudil, R., Jebavy, L., Maly, J.
Формат: Стаття
Мова:Англійська
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2010
Теми:
Онлайн доступ:https://nasplib.isofts.kiev.ua/handle/123456789/138602
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / J.M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 97-99. — Бібліогр.: 26 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
_version_ 1862593114980483072
author Horacek, J.M.
Vasatova, M.
Tichy, M.
Pudil, R.
Jebavy, L.
Maly, J.
author_facet Horacek, J.M.
Vasatova, M.
Tichy, M.
Pudil, R.
Jebavy, L.
Maly, J.
citation_txt The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / J.M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 97-99. — Бібліогр.: 26 назв. — англ.
collection DSpace DC
container_title Experimental Oncology
description Aim: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury — glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Methods: A total of 47 adult acute leukemia patients were studied — 24 patients treated with conventional CT containing anthracyclines (ANT) and 23 patients treated with HD-CT (myeloablative preparative regimen) followed by hematopoietic cell transplantation (HCT). Cardiac biomarkers were assessed prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group, after HD-CT and after HCT in the second group. Values above the reference range were considered elevated. Results: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-offs in all patients. GPBB increased above the cut-off (7.30 μg/L) in 4 (16.7%) patients after first CT and in 5 (20.8%) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7%) patients after HD-CT and remained elevated in 5 (21.7%) patients after HCT. CTnI became elevated (above 0.40 μg/L) in 2 (8.3%) patients after first and last CT with ANT. Both patients with cTnI positivity had elevated GPBB. Other tested biomarkers remained below the cut-offs during the study. Conclusion: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by HCT. The predictive value for development of cardiomyopathy in the future is not known and should be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new circulating biomarkers in the assessment of cardiotoxicity in oncology.
first_indexed 2025-11-27T09:28:54Z
format Article
fulltext
id nasplib_isofts_kiev_ua-123456789-138602
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
issn 1812-9269
language English
last_indexed 2025-11-27T09:28:54Z
publishDate 2010
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
record_format dspace
spelling Horacek, J.M.
Vasatova, M.
Tichy, M.
Pudil, R.
Jebavy, L.
Maly, J.
2018-06-19T10:22:56Z
2018-06-19T10:22:56Z
2010
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia / J.M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2010. — Т. 32, № 2. — С. 97-99. — Бібліогр.: 26 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/138602
Aim: Monitoring of cardiotoxicity of conventional and high-dose chemotherapy (HD-CT) with multiple biomarkers of cardiac injury — glycogen phosphorylase BB (GPBB), heart-type fatty acid binding protein (H-FABP), cardiac troponins (cTnT, cTnI), creatine kinase MB (CK-MB mass), myoglobin. Methods: A total of 47 adult acute leukemia patients were studied — 24 patients treated with conventional CT containing anthracyclines (ANT) and 23 patients treated with HD-CT (myeloablative preparative regimen) followed by hematopoietic cell transplantation (HCT). Cardiac biomarkers were assessed prior to treatment (before CT/HD-CT), after first CT with ANT, after last CT with ANT in the first group, after HD-CT and after HCT in the second group. Values above the reference range were considered elevated. Results: Before CT/HD-CT, all biomarkers of cardiac injury were below the cut-offs in all patients. GPBB increased above the cut-off (7.30 μg/L) in 4 (16.7%) patients after first CT and in 5 (20.8%) patients after last CT with ANT. GPBB increased above the cut-off in 5 (21.7%) patients after HD-CT and remained elevated in 5 (21.7%) patients after HCT. CTnI became elevated (above 0.40 μg/L) in 2 (8.3%) patients after first and last CT with ANT. Both patients with cTnI positivity had elevated GPBB. Other tested biomarkers remained below the cut-offs during the study. Conclusion: Our results suggest that GPBB could become a sensitive biomarker for detection of acute cardiotoxicity associated with conventional CT containing ANT and HD-CT followed by HCT. The predictive value for development of cardiomyopathy in the future is not known and should be evaluated during a prospective follow-up. Based on our data, a larger prospective and multicenter study would be most desirable to define the potential role of new circulating biomarkers in the assessment of cardiotoxicity in oncology.
The work was supported by research projects MO 0FVZ0000503 (Czech Ministry of Defence) and MZO 00179906 (Czech Ministry of Health) and MSM 0021620817 (Czech Ministry of Education).
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
Article
published earlier
spellingShingle The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
Horacek, J.M.
Vasatova, M.
Tichy, M.
Pudil, R.
Jebavy, L.
Maly, J.
Original contributions
title The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
title_full The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
title_fullStr The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
title_full_unstemmed The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
title_short The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
title_sort use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia
topic Original contributions
topic_facet Original contributions
url https://nasplib.isofts.kiev.ua/handle/123456789/138602
work_keys_str_mv AT horacekjm theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT vasatovam theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT tichym theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT pudilr theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT jebavyl theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT malyj theuseofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT horacekjm useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT vasatovam useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT tichym useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT pudilr useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT jebavyl useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia
AT malyj useofcardiacbiomarkersindetectionofcardiotoxicityassociatedwithconventionalandhighdosechemotherapyforacuteleukemia